Brief: Dimerix Ltd Says FDA Approves Commercial Brand Name For Drug Candidate
25/09/2023 02:25
Sept 25 (Reuters) - Dimerix Ltd DXB.AX :
* FDA APPROVES COMMERCIAL BRAND NAME FOR DIMERIX PHASE 3
DRUG
CANDIDATE
Source text for Eikon: ID:nASX39SdWT
Further company coverage: DXB.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dimerix
See all newsAustralia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region
Brief: Everest Medicine In Agreement With Dimerix To Develop Commercialize DMX-200 In Greater China, South Korea, And Southeast Asia
Brief: Dimerix Seeks Trading Halt
Brief: Dimerix To Conduct Review Of Action3 Statistical Assumptions